IPSEN, OOO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

To Document the Effectiveness of BoNT-A Injection in Adult Subjects With Upper Limb Spasticity Following Stroke

Completed

Conditions: Muscle Spasticity

First Posted Date: 2009-11-25

Last Posted Date: 2020-11-06

Lead Sponsor: Ipsen

Target Recruit Count: 469

Registration Number: NCT01020500

Locations: 🇫🇮
Department of Physical and Rehabilitation Medicine/Central Hospital of Central Finland (Site 246005), Jyväskylä, Finland
🇫🇮
Invalidförbundets Rehabiliteringscenter i Lappland (Site 246004), Rovaniemi, Finland
🇫🇮
Neurologiska Polikliniken, Tampere University Hospital (site 246001), Tampere, Finland

and more 93 locations

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

Phase 2

Terminated

Conditions: Carcinoid Syndrome

Interventions: Drug: BIM 23A760

First Posted Date: 2009-11-25

Last Posted Date: 2020-11-20

Lead Sponsor: Ipsen

Target Recruit Count: 8

Registration Number: NCT01018953

Locations: 🇦🇹
University Hospital, Internal Medicine - Oncology, Vienna, Austria
🇮🇱
Rabin Medical Center, Petah Tikva, Israel
🇷🇺
Altay Regional Oncology dispensary, Barnaul, Russian Federation

and more 51 locations

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin (Decapeptyl®)

First Posted Date: 2009-11-25

Last Posted Date: 2019-01-30

Lead Sponsor: Ipsen

Target Recruit Count: 339

Registration Number: NCT01020448

Locations: 🇪🇸
Hospital Juan Canalejo, Coruña, Spain
🇬🇧
Lister Hospital, Stevenage, United Kingdom
🇫🇷
Hôpital Pellegrin, Bordeaux, France

and more 56 locations

Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

Phase 2

Terminated

Conditions: Acromegaly

Interventions: Drug: BIM 23A760

First Posted Date: 2009-10-14

Last Posted Date: 2019-11-22

Lead Sponsor: Ipsen

Target Recruit Count: 109

Registration Number: NCT00994214

Locations: 🇺🇸
Pituitary Center, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital / Neuroendocrine Unit, Boston, Massachusetts, United States
🇧🇪
UZ Leuven, Leuven, Belgium

and more 20 locations

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: BN83495
Drug: Megestrol Acetate (MA)

First Posted Date: 2009-05-29

Last Posted Date: 2019-01-30

Lead Sponsor: Ipsen

Target Recruit Count: 73

Registration Number: NCT00910091

Locations: 🇧🇪
Centre Jules Bordet, Bruxelles, Belgium
🇧🇪
Onze-Lieve-Vrouwzickenhuis-Campus Aalst, Aalst, Belgium
🇫🇷
Hôpital Jean Minjoz, Besançon, France

and more 51 locations

Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study

Phase 3

Completed

Conditions: Precocious Puberty

Interventions: Drug: Triptorelin (I.N.N.)

First Posted Date: 2009-05-29

Last Posted Date: 2019-01-15

Lead Sponsor: Ipsen

Target Recruit Count: 35

Registration Number: NCT00909844

Locations: 🇫🇷
Hôpital des Enfants, Toulouse, France
🇫🇷
Hôpital Hôtel Dieu (CHU), Angers, France
🇫🇷
Hôpital Flaubert, Le Havre, France

and more 7 locations

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Recruiting

Conditions: IGF1 Deficiency

First Posted Date: 2009-05-15

Last Posted Date: 2024-11-28

Lead Sponsor: Ipsen

Target Recruit Count: 500

Registration Number: NCT00903110

Locations: 🇺🇸
University of Miami Leonard M Miller, Miami, Florida, United States
🇺🇸
University Of Miami Leonard M. Miller, Miami, Florida, United States
🇺🇸
D&H National Research Centers, Miami, Florida, United States

and more 54 locations

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea

Phase 2

Completed

Conditions: Diarrhea

Interventions: Drug: lanreotide (Autogel formulation)

First Posted Date: 2009-05-01

Last Posted Date: 2019-01-15

Lead Sponsor: Ipsen

Target Recruit Count: 42

Registration Number: NCT00891371

Locations: 🇧🇪
OLVZ Aalst, Aalst, Belgium
🇧🇪
AZ Maria Middelares, Gent, Belgium
🇧🇪
AZ Sint-Augustinus, Wilrijk, Belgium

and more 8 locations

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

Phase 3

Completed

Conditions: Non Functioning Entero-pancreatic Endocrine Tumour

Interventions: Drug: lanreotide (Autogel formulation)

First Posted Date: 2009-02-12

Last Posted Date: 2022-10-12

Lead Sponsor: Ipsen

Target Recruit Count: 89

Registration Number: NCT00842348

Locations: 🇮🇹
Centro di Refierimiento Oncologica, Aviano, Italy
🇮🇹
University of Naples, Naples, Italy
🇺🇸
Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States

and more 22 locations

Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia

Completed

Conditions: Idiopathic Cervical Dystonia

First Posted Date: 2009-01-30

Last Posted Date: 2019-08-16

Lead Sponsor: Ipsen

Target Recruit Count: 404

Registration Number: NCT00833196

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, Australia
🇦🇺
St Vincent's Hospital, Fitzroy, Australia
🇧🇪
UZ Gent, Gent, Belgium

and more 33 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy